David Lubner

David Charles Lubner is currently an Independent Director at Crescent Biopharma, Inc. (since 2025), Gemini Therapeutics Sub, Inc. (since 2020), Cerevance, Inc. (since 2020), Dyne Therapeutics, Inc. (since 2020), and Ichnos Glenmark Innovation, Inc. He is also a Non-Executive Director at Ichnos Glenmark Innovation, Inc., a Member of The American Institute of Certified Public Accountants, and a Partner at RA Capital Management LP (Private Equity) starting in 2025.
Former roles include Director at NightstaRx Ltd., Independent Non-Executive Director at Nightstar Therapeutics Ltd. (2017–2019), Independent Director at Therapeutics Acquisition Corp.
(2020–2021), Independent Director at Vor Biopharma, Inc. (2020–2025), Independent Director at Cargo Therapeutics, Inc. (2023–2025), Independent Director at Gemini Therapeutics, Inc. (2020–2022), Independent Director at POINT Biopharma Global, Inc. (2021–2023), Independent Director at Arcellx, Inc. (2020–2026), Chief Financial Officer at PharMetrics, Inc. (1999–2005), Chief Financial Officer & Senior Vice President at Tetraphase Pharmaceuticals, Inc. (2010–2016), Chief Financial Officer, Secretary & Executive VP at RA Pharmaceuticals, Inc. (2016–2020), and Chief Financial Officer & Vice President at ProScript, Inc. (1996–1999).
Education includes a graduate degree from Bentley University (1993) and an undergraduate degree from Northeastern University (1987).